Cargando…
First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers
Inappropriate and chronic activation of the cytosolic NOD‐, LRR‐, and pyrin domain‐containing 3 (NLRP3) inflammasome, a key component of innate immunity, likely underlies several inflammatory diseases, including coronary artery disease. This first‐in‐human phase I trial evaluated safety, pharmacokin...
Autores principales: | Tang, Fei, Kunder, Rebecca, Chu, Tom, Hains, Avis, Nguyen, Allen, McBride, Jacqueline M., Zhong, Yu, Santagostino, Sara, Wilson, Maria, Trenchak, Abigail, Chen, Liuxi, Ly, Justin, Moein, Anita, Lewin‐Koh, Nicholas, Raghavan, Vibha, Osaghae, Uyi, Wynne, Chris, Owen, Ryan, Place, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499406/ https://www.ncbi.nlm.nih.gov/pubmed/37350225 http://dx.doi.org/10.1111/cts.13576 |
Ejemplares similares
-
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC‐0214 in healthy volunteers
por: Zhu, Rui, et al.
Publicado: (2022) -
Translational and pharmacokinetic‐pharmacodynamic application for the clinical development of GDC‐0334, a novel TRPA1 inhibitor
por: Chan, Phyllis, et al.
Publicado: (2021) -
2394. Comparative Analysis of Behavior Change and Vaccine Uptake Beliefs
por: Walsh, Tyler, et al.
Publicado: (2023) -
PB2394: PTPRJ AS A ROBUST DIFFERENTIATING MARKER IN MANTLE CELL LYMPHOMA
por: Valentin Hansen, Simone, et al.
Publicado: (2023) -
GDC respond to crisis
Publicado: (2020)